Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9260321 | 0.81 | CYP1A2 (0.33) | EPHX1ALDH1A1HSD17B10 | |
| SCHEMBL457691 | 0.77 | — | — | |
| SCHEMBL5328559 | 0.75 | — | — | |
| SCHEMBL7140181 | 0.75 | — | — | |
| SCHEMBL2138350 | 0.74 | EPHX1 (0.41) | TP53EPHX1ALDH1A1HSD17B10 | |
| SCHEMBL2762997 | 0.73 | TSHR (0.48) | EPHX1HSD17B10 | |
| SCHEMBL11360513 | 0.73 | — | — | |
| SCHEMBL10676865 | 0.73 | — | — | |
| SCHEMBL8796019 | 0.73 | — | — | |
| SCHEMBL3154127 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2614066-B1 | PROCESS FOR THE PRODUCTION OF CEPHALOSPORINS | DSM SINOCHEM PHARM NL BV (NL) | 2017-11-29 | — | — | EP | claimed |
| EP-2614066-A1 | PROCESS FOR THE PRODUCTION OF CEPHALOSPORINS | DSM Sinochem Pharmaceuticals Netherlands B.V. (NL) | 2013-07-17 | — | — | EP | claimed |
| WO-2012032040-A1 | PROCESS FOR THE PRODUCTION OF CEPHALOSPORINS | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2012-03-15 | — | — | WO | claimed |
| US-6803460-B2 | ACIDIFICATION; CARBONATION | DSM IP ASSETS B.V. (NL) | 2004-10-12 | — | — | US | claimed |
| US-20030139595-A1 | Novel process for the fermentative production of cephalosporin | DSM IP ASSETS B.V. (NL) | 2003-07-24 | — | — | US | claimed |
| US-6552185-B1 | Acidifying and/or contacting with carbon dioxide followed by adsorption chromatography | DSM N.V. (NL) | 2003-04-22 | — | — | US | claimed |
| EP-1066294-B1 | NOVEL PROCESS FOR THE FERMENTATIVE PRODUCTION OF CEPHALOSPORIN | DSM NV (NL) | 2002-10-30 | — | — | EP | claimed |
| EP-2614066-B1 | PROCESS FOR THE PRODUCTION OF CEPHALOSPORINS | DSM SINOCHEM PHARM NL BV (NL) | 2017-11-29 | — | — | EP | disclosed |
| EP-2614066-A1 | PROCESS FOR THE PRODUCTION OF CEPHALOSPORINS | DSM Sinochem Pharmaceuticals Netherlands B.V. (NL) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012032040-A1 | PROCESS FOR THE PRODUCTION OF CEPHALOSPORINS | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2012-03-15 | — | — | WO | disclosed |
| US-6803460-B2 | ACIDIFICATION; CARBONATION | DSM IP ASSETS B.V. (NL) | 2004-10-12 | — | — | US | disclosed |
| CN-1138781-C | Novel process for fermentative production of cephalosporin | DSM | 2004-02-18 | — | — | CN | disclosed |
| US-20030139595-A1 | Novel process for the fermentative production of cephalosporin | DSM IP ASSETS B.V. (NL) | 2003-07-24 | — | — | US | disclosed |
| EP-1066294-A1 | NOVEL PROCESS FOR THE FERMENTATIVE PRODUCTION OF CEPHALOSPORIN | DSM N.V. (NL) | 2001-01-10 | — | — | EP | disclosed |
| EP-1066294-A1 | NOVEL PROCESS FOR THE FERMENTATIVE PRODUCTION OF CEPHALOSPORIN | DSM N.V. (NL) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999050271-A1 | NOVEL PROCESS FOR THE FERMENTATIVE PRODUCTION OF CEPHALOSPORIN | DSM N.V. (NL) | 1999-10-07 | — | — | WO | disclosed |
| WO-1999050271-A1 | NOVEL PROCESS FOR THE FERMENTATIVE PRODUCTION OF CEPHALOSPORIN | DSM N.V. (NL) | 1999-10-07 | — | — | WO | disclosed |
| US-5795733-A | Process for the efficient production of 7-ADCA via 3-(carboxyethylthio) propionyl-7-ADCA | GIST-BROCADES, B.V. (NL) | 1998-08-18 | — | — | US | disclosed |
| EP-0711348-A1 | PROCESS FOR THE EFFICIENT PRODUCTION OF 7-ADCA VIA 3-(CARBOXYETHYLTHIO)PROPIONYL-7-ADCA | GIST-BROCADES B.V. (NL) | 1996-05-15 | — | — | EP | disclosed |
| WO-1995004149-A1 | PROCESS FOR THE EFFICIENT PRODUCTION OF 7-ADCA VIA 3-(CARBOXYETHYLTHIO)PROPIONYL-7-ADCA | GIST-BROCADES B.V. (NL) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139595-A1 | Novel process for the fermentative production of cephalosporin | ACSL6, ADSL, COASY | TP53 4722/4885EPHX1 3342/4885ALDH1A1 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.